Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/23045
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMitra, Akash-
dc.contributor.authorAndrews, Miles C-
dc.contributor.authorRoh, Whijae-
dc.contributor.authorDe Macedo, Marianna Petaccia-
dc.contributor.authorHudgens, Courtney W-
dc.contributor.authorCarapeto, Fernando-
dc.contributor.authorSingh, Shailbala-
dc.contributor.authorReuben, Alexandre-
dc.contributor.authorWang, Feng-
dc.contributor.authorMao, Xizeng-
dc.contributor.authorSong, Xingzhi-
dc.contributor.authorWani, Khalida-
dc.contributor.authorTippen, Samantha-
dc.contributor.authorNg, Kwok-Shing-
dc.contributor.authorSchalck, Aislyn-
dc.contributor.authorSakellariou-Thompson, Donald A-
dc.contributor.authorChen, Eveline-
dc.contributor.authorReddy, Sangeetha M-
dc.contributor.authorSpencer, Christine N-
dc.contributor.authorWiesnoski, Diana-
dc.contributor.authorLittle, Latasha D-
dc.contributor.authorGumbs, Curtis-
dc.contributor.authorCooper, Zachary A-
dc.contributor.authorBurton, Elizabeth M-
dc.contributor.authorHwu, Patrick-
dc.contributor.authorDavies, Michael A-
dc.contributor.authorZhang, Jianhua-
dc.contributor.authorBernatchez, Chantale-
dc.contributor.authorNavin, Nicholas-
dc.contributor.authorSharma, Padmanee-
dc.contributor.authorAllison, James P-
dc.contributor.authorWargo, Jennifer A-
dc.contributor.authorYee, Cassian-
dc.contributor.authorTetzlaff, Michael T-
dc.contributor.authorHwu, Wen-Jen-
dc.contributor.authorLazar, Alexander J-
dc.contributor.authorFutreal, P Andrew-
dc.date2020-04-15-
dc.date.accessioned2020-04-23T04:23:49Z-
dc.date.available2020-04-23T04:23:49Z-
dc.date.issued2020-04-15-
dc.identifier.citationNature communications 2020; 11(1): 1839-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/23045-
dc.description.abstractComplex tumor microenvironmental (TME) features influence the outcome of cancer immunotherapy (IO). Here we perform immunogenomic analyses on 67 intratumor sub-regions of a PD-1 inhibitor-resistant melanoma tumor and 2 additional metastases arising over 8 years, to characterize TME interactions. We identify spatially distinct evolution of copy number alterations influencing local immune composition. Sub-regions with chromosome 7 gain display a relative lack of leukocyte infiltrate but evidence of neutrophil activation, recapitulated in The Cancer Genome Atlas (TCGA) samples, and associated with lack of response to IO across three clinical cohorts. Whether neutrophil activation represents cause or consequence of local tumor necrosis requires further study. Analyses of T-cell clonotypes reveal the presence of recurrent priming events manifesting in a dominant T-cell clonotype over many years. Our findings highlight the links between marked levels of genomic and immune heterogeneity within the physical space of a tumor, with implications for biomarker evaluation and immunotherapy response.-
dc.language.isoeng-
dc.titleSpatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma.-
dc.typeJournal Article-
dc.identifier.journaltitleNature communications-
dc.identifier.affiliationDepartment of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USAen
dc.identifier.affiliationQuantitative Sciences Graduate Training Program, Graduate School of Biomedical Sciences, Houston, Texas, USAen
dc.identifier.affiliationDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USAen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Heidelberg, VIC, Australiaen
dc.identifier.affiliationDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USAen
dc.identifier.affiliationInstitute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USAen
dc.identifier.affiliationDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas, USAen
dc.identifier.affiliationDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USAen
dc.identifier.affiliationDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USAen
dc.identifier.affiliationDepartment of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USAen
dc.identifier.affiliationDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USAen
dc.identifier.affiliationThe Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USAen
dc.identifier.affiliationParker Institute for Cancer Immunotherapy, San Francisco, California, USAen
dc.identifier.affiliationAstraZeneca, Gaithersburg, Maryland, USAen
dc.identifier.affiliationDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USAen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1038/s41467-020-15538-9-
dc.identifier.orcid0000-0002-0633-1615-
dc.identifier.orcid0000-0003-1231-8641-
dc.identifier.orcid0000-0002-7395-9939-
dc.identifier.orcid0000-0002-0434-7605-
dc.identifier.orcid0000-0001-8312-7485-
dc.identifier.orcid0000-0003-4510-0382-
dc.identifier.orcid0000-0003-0364-7443-
dc.identifier.orcid0000-0003-1059-0940-
dc.identifier.orcid0000-0002-0977-0912-
dc.identifier.orcid0000-0001-5412-9860-
dc.identifier.orcid0000-0003-3438-7576-
dc.identifier.orcid0000-0002-6395-4499-
dc.identifier.orcid0000-0001-8663-2671-
dc.identifier.pubmedid32296058-
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.